Document is current
Any future updates will be listed below
-
Authors
Cevikbas, Ferda https://orcid.org/0009-0007-7518-1757
Ward, Alison https://orcid.org/0009-0003-2201-8850
Veverka, Karen A. https://orcid.org/0009-0009-9222-192X
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04090229 at ClinicalTrials.govDocuments that mention this clinical trial
Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis
https://doi.org/10.1007/s40259-024-00685-y
-
Funding
Funding for this research was provided by:
ASLAN Pharmaceuticals Pte Ltd
- License Information
-
More Information
Article History
Accepted: 25 September 2024
First Online: 15 October 2024
Declarations
:
: This study was funded by ASLAN Pharmaceuticals Pte Ltd, Singapore and San Mateo, CA USA.
: Drs Cevikbas and Veverka are former employees and Dr Ward was a consultant of ASLAN Pharmaceuticals Pte Ltd at the time of submission.
: Datasets related to this article can be provided upon request by the corresponding author.
: Not applicable.
: The conduct of the study was guided by the principles of the Declaration of Helsinki and in compliance with International Council for Harmonization and Good Clinical Practice guidelines; and was approved by the Domain Specific Review Board (DSRB) in Singapore, Bellberry Human Research Ethics Committee in South Australia, and Advarra Center for IRB Intelligence (CIRBI) in USA.
: Written informed consent was obtained from all patients prior to participation in the study.
: Not applicable.
: Conceptualization and study design: AW; Data acquisition, analysis, and interpretation: FC, AW, KV; Supervision: KV; Writing – Original draft preparation: KV, FC; Writing – review and editing: KV, FC, AW. All authors read and approved the final manuscript.
